General fitness, health and nutrition · Public discussion

Jan Drew Thanks God For Elavil

Started by Rich · · Last activity · 1 post · 296 views

Thread details

What we know about this thread

Original section
General fitness, health and nutrition
Published
27 December 2003
Last activity
27 December 2003
Original author
Rich
Posts
1
Discussion status
Public discussion
Total views
296
Views / 30 days
0

The navigation and discussion metadata provide context. Posts remain in their original chronological order.

Showing posts 1–1 of 1
Posts remain in their original chronological order.

Text size
  1. Jan Drew says that she thanks God for Elavil. But she is just being a
    shill for the pharmaceutical companies. Now for the truth Ruth.
    http://www.prozactruth.com/amitriptyline.htm

    Amitriptyline Elavil. Find out the true side effects. Elavil side
    effects, warnings, precautions, adverse effects, overdose, withdrawal
    symptoms and Elavil natural alternatives. Before you begin the spiral
    down with these drugs, try giving your body what it really wants.

    Report medication side effects to the FDA.

    Real Side Effects Detoxification How to Taper

    Are you having a difficult time quitting Amitriptyline?

    Do you want to keep taking Amitriptyline but you want to get rid of
    the side effects or help protect your body from the Amitriptyline
    toxins?

    --------------------------------------------------------------------------------

    Indications
    In the drug management of depressive illness.
    Amitriptyline may be used in depressive illness of psychotic or
    endogenous nature and in selected patients with neurotic depression.
    Endogenous depression is more likely to be alleviated than are other
    depressive states. Amitriptyline, because of its sedative action, is
    also of value in alleviating the anxiety component of depression.

    As with other tricyclic antidepressants, amitriptyline may precipitate
    hypomanic episodes in patients with bipolar depression. These drugs
    are not indicated in mild depressive states and depressive reactions.

    --------------------------------------------------------------------------------

    Contraindications Back to top of page
    In patients who have shown prior hypersensitivity to it. It should not
    be given concomitantly with a MAO inhibiting compound. Hyperpyretic
    crises, severe convulsions, and deaths have occurred in patients
    receiving tricyclic antidepressant and MAO inhibiting drugs
    simultaneously. When it is desired to substitute amitriptyline for a
    MAO inhibitor, a minimum of 14 days should be allowed to elapse after
    the latter is discontinued. Amitriptyline should then be initiated
    cautiously with gradual increase in dosage until optimum response is
    achieved.
    This drug is not recommended for use during the acute recovery phase
    following myocardial infarction and in the presence of acute
    congestive heart failure.

    See Pregnancy under Warnings.

    --------------------------------------------------------------------------------

    Warnings Back to top of page
    Amitriptyline should be used with caution in patients with a history
    of seizures, impaired liver function, a history of hepatic damage or
    blood dyscrasias and, because of its atropine-like action, in patients
    with a history of urinary retention, or with narrow-angle glaucoma or
    increased intraocular pressure. In patients with narrow-angle
    glaucoma, even average doses may precipitate an attack.
    There has been a report of fatal dysrhythmia occurring as late as 56
    hours after amitriptyline overdose.

    Patients with cardiovascular disorders should be watched closely.
    Tricyclic antidepressant drugs, including amitriptyline, particularly
    when given in high doses, have been reported to produce arrhythmias,
    sinus tachycardia, and prolongation of the conduction time.

    A few instances of unexpected deaths have been reported in patients
    with cardiovascular disorders. Myocardial infarction and stroke have
    also been reported with drugs of this class. Therefore, these drugs
    should be used with caution in patients with a history of
    cardiovascular disease, such as myocardial infarction and congestive
    heart failure.

    Concurrent administration of amitriptyline and electroshock therapy
    may increase the hazards of therapy. Such treatment should be limited
    to patients for whom it is essential.

    Close supervision is required when amitriptyline is given to
    hyperthyroid patients or those receiving thyroid medication.

    Occupational Hazards: Back to top of page

    May impair mental and/or physical abilities required for performance
    of hazardous tasks, such as operating machinery or driving a motor
    vehicle.

    Pregnancy:
    There are no well-controlled studies in pregnant women; therefore, in
    administering the drug to pregnant patients or women who may become
    pregnant, the potential benefits must be weighed against the possible
    hazards to mother and child.

    Lactation:
    Amitriptyline is detectable in breast milk. Because of the potential
    for serious adverse reactions in infants from amitriptyline, a
    decision should be made whether to discontinue nursing or discontinue
    the drug.

    Children:
    In view of the lack of experience with the use of this drug in the
    treatment of depression in children, amitriptyline is not recommended
    for depressed patients under 12 years of age.

    --------------------------------------------------------------------------------

    Precautions Back to top of page
    The potency of amitriptyline is such that addition of other
    antidepressant drugs generally does not result in any additional
    therapeutic benefit. Untoward reactions have been reported after the
    combined use of antidepressant agents having varying modes of
    activity. Accordingly, combined use of amitriptyline and other
    antidepressant drugs should be undertaken only with due recognition of
    the possibility of potentiation and with a thorough knowledge of the
    pharmacology of both drugs. There has been no reports of untoward
    events when patients receiving amitriptyline were changed immediately
    to protriptyline or vice versa.
    When amitriptyline is used to treat the depressive component of
    schizophrenia, activation or aggravation of existing psychotic
    manifestation may occur. Likewise, manic depressive patients may
    experience hypomanic or manic episodes and hyperactive or agitated
    patients may become overstimulated. Paranoid delusions, with or
    without associated hostility, may be exaggerated. A reduction in dose
    or discontinuation of amitriptyline may be indicated and
    administration of a neuroleptic such as a phenothiazine, be considered
    under these circumstances.

    Seriously depressed patients should be carefully supervised. The
    possibility of suicide in depressed patients remains during treatment.
    Patients should not have access to large quantities of this drug
    during treatment.

    Discontinue the drug several days before elective surgery if possible.

    Drug Interactions: Back to top of page

    Amitriptyline may block the antihypertensive action of guanethidine or
    similarly acting compounds.

    When amitriptyline is given with anticholinergic agents or
    sympathomimetic drugs, including epinephrine combined with local
    anesthetics, close supervision and careful adjustment of dosage are
    required. Paralytic ileus may occur in patients taking tricyclic
    antidepressants in combination with anticholinergic-type drugs.

    Since amitriptyline, in combination with anticholinergic type drugs,
    may give rise to paralytic ileus, particularly in elderly or
    hospitalized patients, appropriate measures should be taken if
    constipation occurs in these patients.

    Cimetidine is reported to reduce hepatic metabolism of certain
    tricyclic antidepressants.

    Caution is advised if patients receive large doses of ethchlorvynol
    concurrently. Transient delirium has been reported in patients who
    were treated with 1 g of ethchlorvynol and 75 to 150 mg of
    amitriptyline.

    Amitriptyline may enhance the response to alcohol and the effects of
    barbiturates and other CNS depressants. Delirium has been reported
    with concurrent administration of amitriptyline and disulfiram.

    Note:
    Included in this listing which follows are a few adverse reactions
    which have not been reported with this specific drug. However,
    pharmacological similarities among the tricyclic antidepressant drugs
    require that each of the reactions be considered when amitriptyline is
    administered.

    Behavioral:
    Drowsiness, fatigue, activation of latent schizophrenia,
    disorientation, confusional states, hallucinations, delusions,
    hypomanic reactions, disturbed concentration, nightmares, insomnia,
    restlessness, agitation, excitement, jitteriness, anxiety, giddiness.

    Neurological:
    Epileptiform seizures, coma, dizziness, tremors, numbness, tingling,
    paresthesias of the extremities, peripheral neuropathy, headache,
    ataxia, alteration in EEG patterns, extrapyramidal symptoms including
    abnormal involuntary movements and tardive dyskinesia, dysarthria,
    tinnitus, incoordination, and slurred speech.

    Anticholinergic:
    Urinary retention, dilatation of the urinary tract, constipation,
    paralytic ileus, especially in the elderly, hyperpyrexia, dry mouth,
    blurred vision, disturbance of accommodation, increased intraocular
    pressure, precipitation of latent glaucoma, aggravation of existing
    glaucoma, and mydriasis.

    Cardiovascular:
    Quinidine-like effect and other non-specific ECG changes and changes
    in AV conduction, prolonged conduction time, asystole, hypotension,
    syncope, hypertension, palpitation, arrhythmias, heart block,
    ventricular tachycardia, fibrillation, myocardial infarction, stroke,
    unexpected death in patients with cardiovascular disorders.

    Hematologic:
    Bone marrow depression, including agranulocytosis, leukopenia,
    eosinophilia, purpura, thrombocytopenia.

    Allergic:
    Skin rash, urticaria, photosensitization, edema of the face and
    tongue, itching.

    Gastrointestinal:
    Nausea, epigastric distress, heartburn, vomiting, hepatitis (including
    altered liver function and jaundice), anorexia, stomatitis, peculiar
    taste, diarrhea, parotid swelling, black tongue may occur.

    Endocrine:
    Testicular swelling, gynecomastia and impotence in the male, breast
    enlargement and galactorrhea in the female, increased or decreased
    libido, elevation and lowering of blood sugar levels, syndrome of
    inappropriate ADH (antidiuretic hormone) secretion.

    Miscellaneous:
    Weakness, increased perspiration, edema, urinary frequency, alopecia,
    increased appetite, weight gain, weight loss.

    Withdrawal Symptoms:
    Abrupt cessation of treatment after prolonged administration may
    produce nausea, headache, and malaise. Gradual dosage reduction has
    been reported to produce, within 2 weeks, transient symptoms including
    irritability, restlessness, and dream and sleep disturbance. These
    symptoms are not indicative of addiction. Rare instances have been
    reported of mania or hypomania occurring within 2 to 7 days following
    cessation of chronic therapy with tricyclic antidepressants.

    Aloha,

    Rich
    ------------------------------------------------
    ------------------------------------------------

    The best defense to logic is ignorance.

Active in the last 60 minutes

Active in this thread

0 users · 0 guests ·0 bots ·0 total

No signed-in users are active right now.

No known search crawlers active right now.